Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activity
Restricted accessResearch articleFirst published online June, 2020
Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activity
Programmed cell death protein 1 (PD-1) pathway plays important roles in systemic lupus erythematosus (SLE). We aimed to elucidate the association of serum soluble PD-1 (sPD-1) and related molecules with SLE and to explore their usefulness as biomarkers.
Methods
We retrospectively measured the serum levels of sPD-1, soluble PD-ligand 1 (sPD-L1), soluble PD-ligand 2 (sPD-L2) and interleukin (IL)-21 by ELISA in SLE patients, systemic sclerosis patients and healthy controls. Repeat sera samples were also obtained post treatment.
Results
The serum levels of sPD-1 and sPD-L2 in SLE patients with high disease activity were significantly higher than those in SLE patients with low disease activity, systemic sclerosis patients and healthy controls (n = 58, 15, 20 and 21, respectively; p < 0.001). However, the serum levels of sPD-L1 and IL-21 were not elevated in SLE patients. The serum levels of sPD-1 and sPD-L2 were higher among active SLE patients who tested positive for anti-dsDNA antibodies than in those who tested negative (p = 0.002 and <0.001, respectively). There were moderate correlations between the serum levels of sPD-1 and sPD-L2 and the SLE Disease Activity Index 2000 scores, the titres of anti-dsDNA antibodies and the serum levels of complements. Furthermore, the serum levels of sPD-1 and sPD-L2 decreased significantly in accordance with disease amelioration following treatment (p < 0.001).
Conclusion
The present study demonstrated the association of serum sPD-1 and sPD-L2 with SLE and suggests their usefulness as disease activity biomarkers for SLE.
TsokosGCLoMSCosta ReisPSullivanKE.New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol2016;
12: 716–730.
3.
CrottyS.Follicular helper CD4 T cells (TFH). Annu Rev Immunol2011;
29: 621–663.
4.
BlancoPUenoHSchmittN.T follicular helper (Tfh) cells in lupus: activation and involvement in SLE pathogenesis. Eur J Immunol2016;
46: 281–290.
5.
BocharnikovAVKeeganJWaclecheVS, et al.
PD-1hiCXCR5- T peripheral helper cells promote B cell responses in lupus via MAF and IL-21. JCI Insight2019;
4.
6.
GensousNSchmittNRichezCUenoHBlancoP. T follicular helper cells, interleukin-21 and systemic lupus erythematosus. Rheumatology (Oxford)2017;
56: 516–523.
7.
ChoiJYHoJHPasotoSG, et al.
Circulating follicular helper-like T cells in systemic lupus erythematosus: association with disease activity. Arthritis Rheumatol2015;
67: 988–999.
8.
FranciscoLMSagePTSharpeAH.The PD-1 pathway in tolerance and autoimmunity. Immunol Rev2010;
236: 219–242.
9.
NishimuraHNoseMHiaiHMinatoNHonjoT.Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity1999;
11: 141–151.
10.
KristjansdottirHSteinssonKGunnarssonIGröndalGErlendssonKAlarcón-RiquelmeME.Lower expression levels of the programmed death 1 receptor on CD4+CD25+ T cells and correlation with the PD-1.3A genotype in patients with systemic lupus erythematosus. Arthritis Rheum2010;
62: 1702–1711.
11.
GuDAoXYangYChenZXuX. Soluble immune checkpoints in cancer: production, function and biological significance. J Immunother Cancer2018;
6: 132.
12.
DaiSJiaRZhangXFangQHuangL.The PD-1/PD-Ls pathway and autoimmune diseases. Cell Immunol2014;
290: 72–79.
13.
NielsenCOhm-LaursenLBaringtonTHusbySLillevangST.Alternative splice variants of the human PD-1 gene. Cell Immunol2005;
235: 109–116.
14.
SongMYParkSHNamHJChoiDHSungYC.Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1. J Immunother2011;
34: 297–306.
15.
HeLZhangGHeYZhuHZhangHFengZ.Blockade of B7-H1 with sPD-1 improves immunity against murine hepatocarcinoma. Anticancer Res2005;
25: 3309–3313.
16.
FrigolaXInmanBAKrcoCJ, et al.
Soluble B7-H1: differences in production between dendritic cells and T cells. Immunol Lett2012;
142: 78–82.
17.
ChenYWangQShiB, et al.
Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. Cytokine2011;
56: 231–238.
18.
LiYXiaoYSuM, et al.
Role of soluble programmed death-1 (sPD-1) and sPD-ligand 1 in patients with cystic echinococcosis. Exp Ther Med2016;
11: 251–256.
19.
HeXHLiuYXuLHZengYY.Cloning and identification of two novel splice variants of human PD-L2. Acta Biochim Biophys Sin (Shanghai)2004;
36: 284–289.
20.
GreisenSRRasmussenTKStengaard-PedersenK, et al.
Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis. Scand J Rheumatol2014;
43: 101–108.
21.
WanBNieHLiuA, et al.
Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol2006;
177: 8844–8850.
22.
YanabaKHayashiMYoshiharaYNakagawaH.Serum levels of soluble programmed death-1 and programmed death ligand-1 in systemic sclerosis: association with extent of skin sclerosis. J Dermatol2016;
43: 954–957.
23.
FukasawaTYoshizakiAEbataS, et al.
Contribution of soluble forms of programmed death 1 and programmed death ligand 2 to disease severity and progression in systemic sclerosis. Arthritis Rheumatol2017;
69: 1879–1890.
24.
YoonTAhnSSJungSMSongJJParkYBLeeSW.Serum soluble programmed cell death protein 1 could predict the current activity and severity of antineutrophil cytoplasmic antibody-associated vasculitis: a monocentric prospective study. Clin Exp Rheumatol2019;
37: 116–121.
25.
AarslevKDigeAGreisenSR, et al.
Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis. Scand J Gastroenterol2017;
52: 93–99.
26.
WuHMiaoMZhangGHuYMingZZhangX.Soluble PD-1 is associated with aberrant regulation of T cells activation in aplastic anemia. Immunol Invest2009;
38: 408–421.
27.
HerMKimDOhMJeongHChoiI.Increased expression of soluble inducible costimulator ligand (ICOSL) in patients with systemic lupus erythematosus. Lupus2009;
18: 501–507.
28.
TanEMCohenASFriesJF, et al.
The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982;
25: 1271–1277.
29.
HochbergMC.Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997;
40: 1725.
CookRJGladmanDDPericakDUrowitzMB.Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity. J Rheumatol2000;
27: 1892–1895.
32.
Van Den HoogenFKhannaDFransenJ, et al.
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum2013;
65: 2737–2747.
33.
ChenYLiMLiuJ, et al.
sPD-L1 expression is associated with immunosuppression and infectious complications in patients with acute pancreatitis. Scand J Immunol2017;
86: 100–106.
34.
LiuTHouYDaiTJYanCZ.Upregulation of interleukin 21 and interleukin 21 receptor in patients with dermatomyositis and polymyositis. Chin Med J (Engl)2017;
130: 2101–2106.
35.
AlessandriCCicciaFPrioriR, et al.
CD4 T lymphocyte autophagy is upregulated in the salivary glands of primary Sjögren’s syndrome patients and correlates with focus score and disease activity. Arthritis Res Ther2017;
19: 178.
36.
LeeYHWooJHChoiSJJiJDSongGG.Association of programmed cell death 1 polymorphisms and systemic lupus erythematosus: a meta-analysis. Lupus2009;
18: 9–15.
37.
AllenCDOkadaTCysterJG.Germinal-center organization and cellular dynamics. Immunity2007;
27: 190–202.
38.
GitlinADMayerCTOliveiraTY, et al.
T cell help controls the speed of the cell cycle in germinal center B cells. Science2015;
349: 643–646.
39.
VinuesaCGSanzICookMC.Dysregulation of germinal centres in autoimmune disease. Nat Rev Immunol2009;
9: 845–857.
40.
LiuMFWengCTWengMY.Variable increased expression of program death-1 and program death-1 ligands on peripheral mononuclear cells is not impaired in patients with systemic lupus erythematosus.J Biomed Biotechnol2009;
2009: 406136.
41.
LatchmanYWoodCRChernovaT, et al.
PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol2001;
2: 261–268.
42.
GhiottoMGauthierLSerriariN, et al.
PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. Int Immunol2010;
22: 651–660.
43.
WongCKWongPTTamLSLiEKChenDPLamCW.Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity. J Clin Immunol2010;
30: 45–52.
44.
LanYLuoBWangJLJiangYWWeiYS.The association of interleukin-21 polymorphisms with interleukin-21 serum levels and risk of systemic lupus erythematosus. Gene2014;
538: 94–98.
45.
LeeJShinEKLeeSY, et al.
Oestrogen up-regulates interleukin-21 production by CD4(+) T lymphocytes in patients with systemic lupus erythematosus. Immunology2014;
142: 573–580.
46.
WangLZhaoPMaL, et al.
Increased interleukin 21 and follicular helper T-like cells and reduced interleukin 10+ B cells in patients with new-onset systemic lupus erythematosus. J Rheumatol2014;
41: 1781–1792.
47.
BaechlerECBatliwallaFMKarypisG, et al.
Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A2003;
100: 2610–2615.
48.
PanHFWuGCFanYG, et al.
Decreased serum level of IL-21 in new-onset systemic lupus erythematosus patients. Rheumatol Int2013;
33: 2337–2342.
49.
McPheeCGBubierJASprouleTJ, et al.
IL-21 is a double-edged sword in the systemic lupus erythematosus-like disease of BXSB.Yaa mice. J Immunol2013;
191: 4581–4588.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
